Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.80 |
| ▸ | RAB9A | P51151 | 3/20 | 0.80 |
| ▸ | MAPT | P10636 | 3/20 | 0.80 |
| ▸ | TP53 | P04637 | 3/20 | 0.80 |
| ▸ | NPC1 | O15118 | 2/20 | 0.80 |
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | NOTUM | Q6P988 | 5/20 | 0.65 |
| ▸ | HSD17B3 | P37058 | 2/20 | 0.55 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.55 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1950238 | 0.90 | TP53 (0.65) | SMN1; SMN2RAB9AMAPTTP53NPC1 | |
| SCHEMBL6668625 | 0.82 | HSD17B3 (0.57) | SMN1; SMN2RAB9AMAPTTP53NPC1 | |
| SCHEMBL11682254 | 0.82 | SMN1; SMN2 (0.70) | SMN1; SMN2RAB9AMAPTTP53NPC1 | |
| SCHEMBL3767593 | 0.80 | SMN1; SMN2 (0.72) | SMN1; SMN2RAB9AMAPTTP53NPC1 | |
| SCHEMBL5009163 | 0.80 | NOTUM (1.00) | MAPTNOTUMHSD17B3TRIM24HTT | |
| SCHEMBL1948510 | 0.80 | NOTUM (0.64) | SMN1; SMN2RAB9AMAPTTP53NPC1 | |
| SCHEMBL14871647 | 0.80 | TMPRSS2 (0.76) | SMN1; SMN2RAB9AMAPTTP53NPC1 | |
| SCHEMBL14067268 | 0.78 | SMN1; SMN2 (0.65) | SMN1; SMN2RAB9AMAPTTP53NPC1 | |
| SCHEMBL13002857 | 0.77 | NOTUM (0.65) | SMN1; SMN2RAB9AMAPTTP53NPC1 | |
| SCHEMBL14067050 | 0.77 | SMN1; SMN2 (0.64) | SMN1; SMN2RAB9AMAPTTP53NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2438055-B1 | DIHYDROINDOLE AND TETRAHYDROISOQUINOLINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS | JAPAN TOBACCO INC (JP) | 2018-10-24 | — | — | EP | claimed |
| US-8426442-B2 | Compounds | XENTION LTD (GB) | 2013-04-23 | — | — | US | claimed |
| EP-2438055-B1 | DIHYDROINDOLE AND TETRAHYDROISOQUINOLINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS | JAPAN TOBACCO INC (JP) | 2018-10-24 | — | — | EP | disclosed |
| US-8426442-B2 | Compounds | XENTION LTD (GB) | 2013-04-23 | — | — | US | disclosed |
| EP-2438055-A1 | DIHYDROINDOLE AND TETRAHYDROISOQUINOLINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS | Xention Limited (GB) | 2012-04-11 | — | — | EP | disclosed |
| US-20110136860-A1 | Compounds | XENTION LTD. (GB) | 2011-06-09 | — | — | US | disclosed |
| WO-2010139967-A1 | DIHYDROINDOLE AND TETRAHYDROISOQUINOLINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS | XENTION LIMITED (GB) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136860-A1 | Compounds | NR3C2, NR5A1, NR0B2 | SMN1; SMN2 2483/4885RAB9A 956/4885MAPT 4728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.